Blood-Based Colon Cancer Tests Work, But Many Patients Skip Follow-Up

Follow Drugslib on

By Ernie Mundell HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

WEDNESDAY, July 30, 2025 — You try one of the new blood-based tests for colon cancer, and unfortunately, the results come back “abnormal.”

Those are alarming findings, of course. But for too many U.S. patients, no further steps are taken, a new study finds.

“Blood-based colorectal cancer screening is promising, but it only works if individuals complete the follow-up colonoscopy,” said study senior author Dr. Folasade May.

“More efforts are needed to help patients follow through to actually diagnose and treat the disease,” said May, an associate professor of medicine at the David Geffen School of Medicine at UCLA.

Colorectal cancer remains the second-leading cancer killer, with 52,900 related deaths expected during 2025, according to the American Cancer Society.

Luckily, there are ways to spot the disease early, when it is most preventable.

These include colonoscopy (recommended start time is age 45 for people at average risk), stool-based tests, and, more recently, blood-based testing.

The latter is a non-invasive, relatively easy means of cancer screening.

But how often do patients follow up and book an appointment for a colonoscopy (the gold standard for screening) if their blood test comes back “abnormal’?

To find out, May’s team looked at Medicare claims data for more than 6,000 people aged 45 and older who had taken a blood-based colorectal cancer screening test, called Shield (made by Guardant Health), between 2022 and 2024.

A total of 452 users received an abnormal result. Typically, these patients should book a colonoscopy within the next six months to ascertain whether they have a cancer.

The study findings weren’t encouraging: Fewer than half (49%) of patients who received an abnormal result on their Shield test completed follow-up colonoscopy within six months, and that percentage only rose to 56% when the researchers extended follow-up to two years. Rates didn't seem to vary based on race or ethnicity.

The findings are about on par with follow-up rates for folks using stool-based tests, the researchers noted.

People who were using Medicare Advantage programs were significantly less likely to go for follow-up colonoscopy than people with private insurance, the study found.

The bottom line, according to the researchers: “As blood-based colorectal cancer screening technologies become [U.S. Food and Drug Administration] FDA-approved and adopted by physicians and patients, we must prioritize strategies to ensure timely follow-up.”

The findings were published July 29 in the journal Gastroenterology.

Sources

  • University of California Los Angeles, news release, July 29, 2025
  • Gastroenterology, July 29, 2025

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2025-07-31 00:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords